---
layout: post
title: New Drug Approvals 2014 - Pt. VIII - Siltuximab (Sylvant™)
date: '2014-05-17T15:21:00.000+01:00'
author: Bissan Al-Lazikani
tags:
- mAb Drugs
- 2014 New Drugs
modified_time: '2014-05-17T15:21:04.917+01:00'
thumbnail: http://4.bp.blogspot.com/-CvqgG6riJPc/U3Xi_M-wtpI/AAAAAAAAAQE/zjfbGVfQcEE/s72-c/Sylvant.jpeg
blogger_id: tag:blogger.com,1999:blog-2546008714740235720.post-7937830537964716784
blogger_orig_url: http://chembl.blogspot.com/2014/05/new-drug-approvals-2014-pt-viii.html
---

<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="http://4.bp.blogspot.com/-CvqgG6riJPc/U3Xi_M-wtpI/AAAAAAAAAQE/zjfbGVfQcEE/s1600/Sylvant.jpeg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="http://4.bp.blogspot.com/-CvqgG6riJPc/U3Xi_M-wtpI/AAAAAAAAAQE/zjfbGVfQcEE/s320/Sylvant.jpeg" /></a></div>
<br />
<br />
<center>
<img src="https://www.ebi.ac.uk/chembltools/autoiconlarge2/6,0,1,2,0,0,1,0,0,1" width="400" /><br />
<br />
<b>ATC Code:</b><br />
<b>Wikipedia:</b><a href="http://en.wikipedia.org/wiki/Siltuximab">Siltuximab</a><br />
<b>ChEMBL:</b><a href="https://www.ebi.ac.uk/chembl/compound/inspect/CHEMBL1743070">CHEMBL1743070</a><br />
<br /></center>
On April 23rd 2014 the FDA approved Siltuximab (Sylvant™) for the treatment of patients with multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV-)-negative and human herpes virus-8 (HHV-8)-negative.<br />
<br />
Castleman disease (Also known as giant or angiofollicular lymph node hyperplasia, lymphoid hamartoma, or angiofollicular lymph node hyperplasia) is an abnormal non-cancerous growth of the lymph node that can resemble lymphomas. It is contributed to by hyperproliferation of cytokine-producing lymphocytes. Castleman disease can be unicentric (involving a single lymph node) or multicentric (systemic). Siltuximab is approved for the multi centric disease. Overproduction of IL-6 has been linked to systemic manifestations in patients with MCD.<br />
<br />
Siltuximab is a chimeric (human and mouse) anti-IL6 antibody. It binds human IL-6 thus preventing the interaction of IL-6 to both soluble and membrane- bound IL-6 receptors.<br />
<div class="separator" style="clear: both; text-align: center;">
<a href="http://4.bp.blogspot.com/-tetyqtpl1w0/U3XyAzArBzI/AAAAAAAAAQQ/ErgfDxCyBlg/s1600/IL6.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" src="http://4.bp.blogspot.com/-tetyqtpl1w0/U3XyAzArBzI/AAAAAAAAAQQ/ErgfDxCyBlg/s320/IL6.png" /></a></div>
<br />
The target, Interleukin-6 (IL6; Uniprot = <a href="http://www.uniprot.org/uniprot/P05231">P05231</a>; ChEMBL = <a href="https://www.ebi.ac.uk/chembl/target/inspect/CHEMBL1795129">CHEMBL1795129</a> ; canSAR = <a href="https://cansar.icr.ac.uk/cansar/molecular-targets/P05231/">P05231</a>)is an pro-inflammatory cytokine produced by T-lymphocytes and macrophages in response to infection or trauma.<br />
<br />
Siltuximab is produced in Chinese hamster ovary (CHO) cells and dministered as an 11 mg/kg dose given over 1 hour by intravenous infusion every 3 weeks. The maximum serum concentration (Cmax) was observed close to the end of infusion. At steady state, the serum mean Cmax value is 332 mcg/mL (42% CV), and the serum mean predose trough value is 84 mcg/mL (78% CV). The mean terminal half-life (t1/2)  in patients after the first intravenous infusion of 11 mg/kg is 20.6 days, and clearance is 0.23 L/day (51% CV.<br />
<br />
Sylvant™ is a product of <a href="http://www.janssenbiotech.com/">Janssen</a>.<br />
<br />
The full prescribing information can be found <a href="http://www.janssenbiotech.com/sites/default/files/pdf/SYLVANTPrescribingInformation.pdf">here</a>.<br />
<br />